

Global Metastatic Cancer Treatment Market – Focus on Drugs, Competitive Landscape, and Country - Analysis and Forecast (2018-2025)

<https://marketpublishers.com/r/G1AF841D9B03EN.html>

Date: June 2018

Pages: 377

Price: US\$ 4,749.00 (Single User License)

ID: G1AF841D9B03EN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

The healthcare industry is a multi-billion dollars market consisting of various verticals aimed at improving patient lives. With increase in research and developmental activities, technological advancements are being made to make patient services convenient and affordable. Cancer represents one of the major concern of the global healthcare industry, as it is the second leading cause of death all around the world (according to WHO). Cancer statistics has a major impact on society across the world and accounts for almost 70% of death in low- and middle- income countries. As per GLOBOCAN data, there were almost 14 million cancer cases globally in 2012, which claimed almost 8 million patient lives. As a result, enormous scientific innovation is taking place in the field of oncology for the development of novel oncology medicines that are significantly propelling the growth of metastatic cancer treatment market. Metastatic cancer, represents the advanced form of cancer, which occurs when the cancer cells starts spreading from the primary site of origin to different parts of the body. Treatment of metastatic cancer is often not curable and is mainly focussed on providing palliative care. Several companies are investing into oncology market and are making strenuous effort for the delivery of cost-effective cancer treatment drugs used in chemotherapy, radiation therapy, and hormone therapy. Patients all over the world are looking forward for advanced cancer therapy drugs to arrest their condition, which is turn is increasing the adoption rate of the metastatic cancer treatment drugs.

The metastatic cancer treatment market consists of products, such as generic medicines and branded medicines, used in the treatment of metastatic cancer. The

market analysis includes an in-depth examination of the key ecosystem players, key strategies, and developments taking place in this market. Additionally, it includes market dynamics (market drivers, opportunities, and challenges) and industry analysis. The market has been classified based on different therapeutic indications, such as breast cancer, melanoma, colorectal cancer, lung cancer, prostate cancer, and others. Geographically, the market can be segmented into five distinct regions including, North America, Europe, Asia-Pacific, Latin America, and Rest of the World.

The purpose of the study is to gain a holistic view of the global metastatic cancer treatment market in terms of various factors influencing it such as key market trends, competitive and regulatory aspects of the market, scientific innovations into oncology fields, etc. The scope of the report is centered upon conducting a detailed study of the solutions allied with metastatic cancer treatment market, which involves drugs used in different therapeutic applications of cancer treatment such as chemotherapy, hormone therapy, and immunotherapy, among others. The global metastatic cancer treatment market is segmented into three different parts: 'by products', 'by therapeutic indication', and 'by region'. The report offers the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering questions related to various aspects of the global market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global metastatic cancer treatment market, and assesses the factors governing the same. Opportunity matrix and detailed product mapping have been included in the report. The market by region has been further sub-segmented in various countries, and in each sub-segment the key market trends, list of the key players, and recent developments, have been discussed.

The answers to the following key questions can be derived from this report:

What are the major market drivers, restraints, and opportunities in the global metastatic cancer treatment market?

What are the market shares of the leading segments, and sub-segments of the global metastatic cancer treatment market in 2017 and what will be its value in 2026?

How will each segment of the global metastatic cancer treatment market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2026?

What are the influencing factors that may affect the market share of the key players?

What are the key developmental strategies implemented by the key players to stand out in this market?

What are the major Regulatory Authorities/ Associations/ Consortiums affecting the metastatic cancer treatment market and what are the main designations facilitating development and approval of cancer drugs?

Which are the companies holding patent rights for the metastatic cancer treatment drugs and what patent landscape exist in the market?

Which product segment is expected to register the highest CAGR for the global metastatic cancer treatment market?

How has the market been segmented based on therapeutic indication? Which therapeutic indication segment has the largest share, and fastest growth rate in the global metastatic cancer treatment market?

Which geographical region will contribute to the highest sales of the metastatic cancer treatment drugs during the forecast period and which will have the highest CAGR?

What are major companies developing metastatic cancer treatment drugs targeted for different therapeutic indication and what were sales of drugs for the past three years (2015-2017)?

What are the drugs under developmental stages and the companies conducting their clinical study?

The key players that have been contributing significantly include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb

Company, Celgene Corporation, Clovis Oncology, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi and Takeda Pharmaceutical Company Limited, among others.

Contents

EXECUTIVE SUMMARY

1 MARKET OVERVIEW

- 1.1. Introduction to Cancer
- 1.2. Cancer Statistics: Incidence, Survival and Mortality
 - 1.2.1. Important Facts
- 1.3. Metastasis and Metastatic Cancer
 - 1.3.1. Where Cancer Spreads
 - 1.3.1. Ongoing Research and Treatment of Metastatic Cancer
- 1.4. Global Market
- 1.5. FDA Approvals of Oncology Drugs
- 1.6. Assumptions and Limitation

2 MARKET DYNAMICS

- 2.1. Market Dynamics: Impact Analysis
- 2.2. Market Drivers
- 2.3. Market Restraints
- 2.4. Market Opportunities

3 INDUSTRY INSIGHTS

- 3.1. Introduction
- 3.2. Regulatory Scenario
- 3.3. Regulatory Designations
- 3.4. Patent Landscape

4 COMPETITIVE LANDSCAPE

- 4.1. Introduction
- 4.2. Key Developments and Strategies
 - 4.2.1. Product Approvals
 - 4.2.2. Clinical Study
 - 4.2.3. Agreement, Partnership, Joint Venture and Collaboration
 - 4.2.4 Regulatory Designations
 - 4.2.5. Acquisition, Product Launches and Others

- 4.3. Porter's Five Forces Analysis
 - 4.3.1. Bargaining Power of Suppliers
 - 4.3.2. Bargaining Power of Buyers
 - 4.3.3. Threat of New Entrant
 - 4.3.4. Threat of Substitute
 - 4.3.5. Intensity of Competitive Rivalry
- 4.4. Market Share (2014-2017)
- 4.5. Pipeline Analysis

5 GLOBAL METASTATIC CANCER TREATMENT MARKET, BY THERAPEUTIC APPLICATION

- 5.1. Overview
- 5.2. Breast Cancer
 - 5.2.1. Breast Cancer: Types, Secondary Sites and Symptoms
 - 5.2.1.1. Breast Cancer: Molecular Subtypes
 - 5.2.2. Breast Cancer: Incidence, Mortality and Prevalence
 - 5.2.3. Breast Cancer: Market
 - 5.2.4. Breast Cancer: Treatment
- 5.3. Melanoma
 - 5.3.1. Melanoma: Types, Secondary Sites and Symptoms
 - 5.3.2. Melanoma: Incidence, Mortality and Prevalence
 - 5.3.3. Melanoma: Market
 - 5.3.4. Melanoma: Treatment
- 5.4. Prostate Cancer
 - 5.4.1. Prostate Cancer: Types, Secondary Sites and Symptoms
 - 5.4.2. Prostate Cancer: Incidence, Mortality and Prevalence
 - 5.4.3. Prostate Cancer: Market
 - 5.4.4. Prostate Cancer: Treatment
- 5.5. Lung Cancer
 - 5.5.1. Lung Cancer: Types, Secondary Sites and Symptoms
 - 5.5.2. Lung Cancer: Incidence, Mortality and Prevalence
 - 5.5.3. Lung Cancer: Market
 - 5.5.4. Lung Cancer: Treatment
- 5.6. Colorectal Cancer
 - 5.6.1. Colorectal Cancer: Types, Secondary Sites and Symptoms
 - 5.6.2. Colorectal Cancer: Incidence, Mortality and Prevalence
 - 5.6.3. Colorectal Cancer: Market
 - 5.6.4. Colorectal Cancer: Treatment

5.7. Other Cancers

6 GLOBAL METASTATIC CANCER TREATMENT MARKET, BY PRODUCT

6.1. Overview

6.1.1. Generic vs. Branded Drugs

6.2. Role of Branded Medicines in Oncology

6.2.1. Branded Medicines: Market

6.3. Role of Generic Medicines in Oncology

6.3.1. Generic Medicines: Market

6.4. Sales of Oncology Drugs

7 GLOBAL METASTATIC CANCER TREATMENT MARKET, BY REGION

7.1. Overview

7.1.1. Introduction

7.2. North America

7.2.1. The U.S.

7.2.2. Canada

7.3. Europe

7.3.1. Germany

7.3.2. The U.K.

7.3.3. France

7.3.4. Spain

7.3.5. Italy

7.4. Asia Pacific

7.4.1. China

7.4.2. Japan

7.4.3. India

7.5. Latin America

7.5.1. Brazil

7.5.2. Mexico

7.5.3. Argentina

7.6. Rest of the World

8 COMPANY PROFILES

8.1. AbbVie, Inc.

8.1.1. Overview

- 8.1.2. Overall Product Portfolio
 - 8.1.2.1. Product Offerings for Metastatic Cancer Treatment Market
- 8.1.3. Financials
 - 8.1.3.1. Financial Summary
- 8.1.4. Global Presence
- 8.1.5. Recent Developments
- 8.1.6. SWOT Analysis
- 8.2. Amgen, Inc.
 - 8.2.1. Overview
 - 8.2.2. Overall Product Portfolio
 - 8.2.2.1. Product Offerings for Metastatic Cancer Treatment Market
 - 8.2.3. Financials
 - 8.2.3.1. Financial Summary
 - 8.2.4. Global Presence
 - 8.2.5. Recent Developments
 - 8.2.6. SWOT Analysis
- 8.3. AstraZeneca PLC
 - 8.3.1. Overview
 - 8.3.2. Overall Product Portfolio
 - 8.3.2.1. Product Offerings for Metastatic Cancer Treatment Market
 - 8.3.3. Financials
 - 8.3.3.1. Financial Summary
 - 8.3.4. Global Presence
 - 8.3.5. Recent Developments
 - 8.3.6. SWOT Analysis
- 8.4. Bayer AG
 - 8.4.1. Overview
 - 8.4.2. Overall Product Portfolio
 - 8.4.2.1. Product Offerings for Metastatic Cancer Treatment Market
 - 8.4.3. Financials
 - 8.4.3.1. Financial Summary
 - 8.4.4. Global Presence
 - 8.4.5. Recent Developments
 - 8.4.6. SWOT Analysis
- 8.5. Boehringer Ingelheim International GmbH
 - 8.5.1. Overview
 - 8.5.2. Overall Product Portfolio
 - 8.5.2.1. Product Offerings for Metastatic Cancer Treatment Market
 - 8.5.3. Financials

- 8.5.3.1. Financial Summary
- 8.5.4. Global Presence
- 8.5.5. Recent Developments
- 8.5.6. SWOT Analysis
- 8.6. BRISTOL-MYERS SQUIBB COMPANY
 - 8.6.1. Overview
 - 8.6.2. Overall Product Portfolio
 - 8.6.2.1. Product Offerings for Metastatic Cancer Treatment Market
 - 8.6.3. Financials
 - 8.6.3.1. Financial Summary
 - 8.6.4. Global Presence
 - 8.6.5. Recent Developments
 - 8.6.6. SWOT Analysis
- 8.7. CELGENE CORPORATION
 - 8.7.1. Overview
 - 8.7.2. Overall Product Portfolio
 - 8.7.2.1. Product Offerings for Metastatic Cancer Treatment Market
 - 8.7.3. Financials
 - 8.7.3.1. Financial Summary
 - 8.7.4. Global Presence
 - 8.7.5. Recent Developments
 - 8.7.6. SWOT Analysis
- 8.8. Eli-Lilly and Company
 - 8.8.1. Overview
 - 8.8.2. Overall Product Portfolio
 - 8.8.2.1. Product Offerings for Metastatic Cancer Treatment Market
 - 8.8.3. Financials
 - 8.8.3.1. Financial Summary
 - 8.8.4. Global Presence
 - 8.8.5. Recent Developments
 - 8.8.6. SWOT Analysis
- 8.9. F. Hoffmann-La Roche AG
 - 8.9.1. Overview
 - 8.9.2. Overall Product Portfolio
 - 8.9.2.1. Product Offerings for Metastatic Cancer Treatment Market
 - 8.9.3. Financials
 - 8.9.3.1. Financial Summary
 - 8.9.4. Global Presence
 - 8.9.5. Recent Developments

- 8.9.6. SWOT Analysis
- 8.10. JOHNSON & JOHNSON
 - 8.10.1. Overview
 - 8.10.2. Overall Product Portfolio
 - 8.10.2.1. Product Offerings for Metastatic Cancer Treatment Market
 - 8.10.3. Financials
 - 8.10.3.1. Financial Summary
 - 8.10.4. Global Presence
 - 8.10.5. Recent Developments
 - 8.10.6. SWOT Analysis
- 8.11. Merck & Co., Inc.
 - 8.11.1. Overview
 - 8.11.2. Overall Product Portfolio
 - 8.11.2.1. Product Offerings for Metastatic Cancer Treatment Market
 - 8.11.3. Financials
 - 8.11.3.1. Financial Summary
 - 8.11.4. Global Presence
 - 8.11.5. Recent Developments
 - 8.11.6. SWOT Analysis
- 8.12. Novartis AG
 - 8.12.1. Overview
 - 8.12.2. Overall Product Portfolio
 - 8.12.2.1. Product Offerings for Metastatic Cancer Treatment Market
 - 8.12.3. Financials
 - 8.12.3.1. Financial Summary
 - 8.12.4. Global Presence
 - 8.12.5. Recent Developments
 - 8.12.6. SWOT Analysis
- 8.13. Pfizer, Inc.
 - 8.13.1. Overview
 - 8.13.2. Overall Product Portfolio
 - 8.13.2.1. Product Offerings for Metastatic Cancer Treatment Market
 - 8.13.3. Financials
 - 8.13.3.1. Financial Summary
 - 8.13.4. Global Presence
 - 8.13.5. Recent Developments
 - 8.13.6. SWOT Analysis
- 8.14. SANOFI
 - 8.14.1. Overview

- 8.14.2. Overall Product Portfolio
 - 8.14.2.1. Product Offerings for Metastatic Cancer Treatment Market
- 8.14.3. Financials
 - 8.14.3.1. Financial Summary
- 8.14.4. Global Presence
- 8.14.5. Recent Developments
- 8.14.6. SWOT Analysis
- 8.15. Takeda Pharmaceutical Company Limited
 - 8.15.1. Overview
 - 8.15.2. Overall Product Portfolio
 - 8.15.2.1. Product Offerings for Metastatic Cancer Treatment Market
 - 8.15.3. Financials
 - 8.15.3.1. Financial Summary
 - 8.15.4. Global Presence
 - 8.15.5. Recent Developments
 - 8.15.6. SWOT Analysis
- 8.16. bluebird bio, Inc.
 - 8.16.1. Overview
 - 8.16.2. Product Offerings for Metastatic Cancer Treatment Market
- 8.17. Clovis Oncology, Inc.
 - 8.17.1. Overview
 - 8.17.2. Product Offerings for Metastatic Cancer Treatment Market
- 8.18. IDERA PHARMACEUTICALS, INC.
 - 8.18.1. Overview
 - 8.18.2. Product Offerings for Metastatic Cancer Treatment Market
- 8.19. eTheRNA immunotherapies NV
 - 8.19.1. Overview
 - 8.19.2. Product Offerings for Metastatic Cancer Treatment Market

9 REPORT SCOPE AND METHODOLOGY

- 9.1. Scope of the Report
- 9.2. Global Metastatic Cancer Treatment Market Segmentation
- 9.3. Research Methodology
 - 9.3.1. Primary Research
 - 9.3.2. Secondary Research
 - 9.3.3. Key Data Points from Primary Sources
 - 9.3.4. Key Data Points from Secondary Sources
 - 9.3.5. Data Triangulation

- 9.3.6. Top-Down Approach (Segment Wise Analysis)
- 9.3.7. Bottom-Up Approach (Segmental Analysis)
- 9.4. Assumptions and Limitations
- 9.5. Data and Prediction Modelling

10 ANNEXURES

- 10.1. Recent Key Developments and Strategies
- 10.2. Product Mapping
- 10.3. Cancer Data Sheet

List Of Tables

LIST OF TABLES

Table 1 Total Regional Geriatric Population by Region (%), 2015 and 2030

Table 2 Impact of Market Drivers

Table 3 Impact of Market Restraints

Table 4 Market Share (2014-2017)

Table 1.1 Estimated New Cases and Estimated Deaths in 2018 as per American Cancer Society

Table 1.2 GLOBOCAN Data as of 2012

Table 1.3 Common sites of Metastasis for Cancers

Table 1.4 Common Classes of Drugs Under Different Cancer Therapies

Table 1.5 Recent FDA Approvals of Oncology Drugs

Table 2.1 Impact of Market Drivers

Table 2.2 Impact of Market Restraints

Table 2.3 Comparison of R&D Expense 2017 and 2016

Table 2.4 Recent Approval of Metastatic Cancer Drugs

Table 2.5 Side Effects Caused by common Metastatic Cancer Drugs

Table 3.1 Regulatory Scenario Across the World

Table 3.2 Regulatory Designations Across The World

Table 3.3 Patent Landscape

Table 4.1 Factors Affecting the Bargaining Power of Suppliers

Table 4.2 Factors Affecting the Bargaining Power of Buyer

Table 4.3 Factors Affecting Threat of New Entrant

Table 4.4 Factors Affecting the Threat of Substitute

Table 4.5 Factors Affecting the Intensity of Competitive Rivalry

Table 4.6 Market Share of Key Players (2014-2017)

Table 4.7 Pipeline Analysis of Metastatic Cancer Treatment Drugs

Table 5.1 Estimated Incidence, Mortality, and Prevalence of Breast Cancer Worldwide in 2012

Table 5.2 Estimated Incidence and Mortality of Melanoma Worldwide in 2012

Table 5.3 Estimated Incidence, Mortality and Prevalence of Prostate Cancer Worldwide in 2012

Table 5.4 Estimated Incidence, Mortality and Prevalence of Lung Cancer (for both sexes) Worldwide in 2012

Table 5.5 Estimated Incidence, Mortality and Prevalence of Colorectal Cancer (for both sexes) Worldwide in 2012

Table 5.6 Estimated Incidence, Mortality and Prevalence of Different Cancer (for both

sexes) Worldwide in 2012

Table 5.7 List of Companies and Drugs for Various Therapeutic Indication

Table 6.1 List of Common Brand-name Drugs used to treat Metastatic Cancer

Table 6.2 List of Common Generic Drugs used to treat Metastatic Cancer

Table 6.3 Sales of Oncology Drugs

Table 7.1 State-wise distribution of Cancer in India

Table 8.1 List of Tier 1 and Tier 2 Companies

Table 8.2 AbbVie Inc.: Recent Developments

Table 8.3 Amgen, Inc.: Recent Developments

Table 8.4 AstraZeneca PLC: Recent Developments

Table 8.5 Bayer AG: Recent Developments

Table 8.6 Boehringer Ingelheim International GmbH: Recent Developments

Table 8.7 BRISTOL-MYERS SQUIBB COMPANY: Recent Developments

Table 8.8 CELGENE CORPORATION: Recent Developments

Table 8.9 Eli-Lilly and Company: Recent Developments

Table 8.10 F. Hoffmann-La Roche AG: Recent Developments

Table 8.11 JOHNSON & JOHNSON: Recent Developments

Table 8.12 Merck & Co., Inc. : Recent Developments

Table 8.13 Novartis AG: Recent Developments

Table 8.14 Pfizer, Inc.: Recent Developments

Table 8.15 SANOFI: Recent Developments

Table 8.16 Takeda Pharmaceutical Company Limited: Recent Developments

List Of Figures

LIST OF FIGURES

Figure 1 Common Treatments of Cancer

Figure 2 Global Metastatic Cancer Treatment Market (\$Million)

Figure 3 Global Metastatic Cancer Treatment Market by Therapeutic Indication, 2017

Figure 4 Global Metastatic Cancer Treatment Market by Therapeutic Indication, 2025

Figure 5 Global Metastatic Cancer Treatment Market by Products, 2017

Figure 6 Global Metastatic Cancer Treatment Market By Products, 2025

Figure 7 Global Metastatic Cancer Treatment Market by Region, 2017

Figure 8 Global Injectable Drug Delivery Market by Region, 2025

Figure 1.1 Causes of Cancer

Figure 1.2 Common Mechanism of Metastasis

Figure 1.3 Types of Metastatic Cancer (based on how far it has spread)

Figure 1.4 Global Metastatic Cancer Treatment Market, 2016-2025 (\$ Million)

Figure 2.1 Market Dynamics: Drivers, Restraints & Opportunities

Figure 2.2 Targeted Therapies Designed for Different Cancer Types

Figure 3.1 Industry Insights (January 2014-February 2018)

Figure 4.1 Competitive Landscape (January 2014-February 2018)

Figure 4.2 Share of Key Developments and Strategies(January 2014 to March 2018)

Figure 4.3 Product Approvals by Companies

Figure 4.4 Clinical Study, by Companies

Figure 4.5 Product Approvals by Companies

Figure 4.6 Porter's Five Forces Analysis

Figure 5.1 Types of Metastatic Cancer by Therapeutic Indication

Figure 5.2 Global Metastatic Cancer Treatment Market by Therapeutic Indication, 2014-2025 (\$Million)

Figure 5.3 Signs and Symptoms of Metastatic Breast Cancer

Figure 5.4 Common Molecular Subtypes of Breast Cancer

Figure 5.5 Global Metastatic Cancer Treatment Market by Breast Cancer, 2014-2025 (\$ Million)

Figure 5.6 List of Common Metastatic Breast Cancer Drugs

Figure 5.7 Signs and Symptoms of Metastatic Melanoma

Figure 5.8 Global Metastatic Cancer Treatment Market by Melanoma Cancer, 2014-2025 (\$ Million)

Figure 5.9 List of Common Metastatic Melanoma Cancer Drugs

Figure 5.10 Signs and Symptoms of Metastatic Prostate Cancer

Figure 5.11 Global Metastatic Cancer Treatment Market by Prostate Cancer, 2014-2025

(\$ Million)

Figure 5.12 List of Common Metastatic Prostate Cancer Drugs

Figure 5.13 Signs and Symptoms of Metastatic Lung Cancer

Figure 5.14 Global Metastatic Cancer Treatment Market by NSCLC, 2014-2025 (\$ Million)

Figure 5.15 List of Common Metastatic Lung Cancer Drugs

Figure 5.16 Signs and Symptoms of Metastatic Colorectal Cancer

Figure 5.17 Global Metastatic Cancer Treatment Market by Colorectal Cancer, 2014-2025 (\$ Million)

Figure 5.18 List of Common Metastatic Colorectal Cancer Drugs

Figure 5.19 Global Metastatic Cancer Treatment Market by Other Cancers, 2014-2025 (\$ Million)

Figure 6.1 Classification of Anti-Cancer Drugs by Pharma Class

Figure 6.2 Global Metastatic Cancer Treatment Market by Branded Medicines, 2014-2025 (\$ Million)

Figure 6.3 Global Metastatic Cancer Treatment Market by Generic Medicines, 2014-2025 (\$ Million)

Figure 7.1 Global Metastatic Cancer Treatment Market by Region, 2014-2025 (\$Million)

Figure 7.2 North America Metastatic Cancer Treatment Market, 2014-2025 (\$Million)

Figure 7.3 North America Metastatic Cancer Treatment Market by Country, 2014-2025 (\$Million)

Figure 7.4 Cancer Patient Data by Cancers Type in the U.S. (2016)

Figure 7.5 Cancer Patient Data by Cancers Type in Canada (2016)

Figure 7.6 The U.S. Metastatic Cancer Treatment Market, 2014-2025 (\$million)

Figure 7.7 Canada Metastatic Cancer Treatment Market, 2014-2025 (\$million)

Figure 7.8 Europe Metastatic Cancer Treatment Market, 2014-2025 (\$Million)

Figure 7.9 Europe Metastatic Cancer Treatment Market by Country, 2014-2025 (\$Million)

Figure 7.10 Cancer Patient Data by Cancers Type in Germany (2016)

Figure 7.11 Cancer Patient Data by Cancers Type in France (2016)

Figure 7.12 Cancer Patient Data by Cancers Type in Italy (2016)

Figure 7.13 France Metastatic Cancer Treatment Market, 2014-2025 (\$million)

Figure 7.14 Germany Metastatic Cancer Treatment Market, 2014-2025 (\$million)

Figure 7.15 Italy Metastatic Cancer Treatment Market, 2014-2025 (\$million)

Figure 7.16 Netherland Metastatic Cancer Treatment Market, 2014-2025 (\$million)

Figure 7.17 Switzerland Metastatic Cancer Treatment Market, 2014-2025 (\$million)

Figure 7.18 The U.K. Metastatic Cancer Treatment Market, 2014-2025 (\$million)

Figure 7.19 Spain Metastatic Cancer Treatment Market, 2014-2025 (\$million)

Figure 7.20 Sweden Metastatic Cancer Treatment Market, 2014-2025 (\$million)

- Figure 7.21 Austria Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.22 Belgium Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.23 Denmark Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.24 Finland Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.25 Poland Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.26 Russia Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.27 Ireland Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.28 Rest of Europe Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.29 Asia Pacific Metastatic Cancer Treatment Market, 2014-2025 (\$Million)
- Figure 7.30 Asia Pacific Metastatic Cancer Treatment Market by Country, 2014-2025 (\$Million)
- Figure 7.31 Cancer Patient Data by Cancers Type in China (2016)
- Figure 7.32 Cancer Patient Data by Cancers Type in Japan (2016)
- Figure 7.33 Cancer Patient Data by Cancers Type in India (2016)
- Figure 7.35 China Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.36 Japan Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.37 India Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.38 South Korea Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.39 Australia Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.40 Bangladesh Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.41 Malaysia Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.42 New Zealand Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.43 Rest of Asia Pacific Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.44 Latin America Metastatic Cancer Treatment Market, 2014-2025 (\$Million)
- Figure 7.45 Latin America Metastatic Cancer Treatment Market by Country, 2014-2025 (\$Million)
- Figure 7.46 Brazil Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.47 Mexico Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.48 Argentina Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.49 Rest of Latin America Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.50 Rest of the World (RoW) Metastatic Cancer Treatment Market, 2014-2025 (\$Million)
- Figure 7.51 Rest of the World (RoW) Metastatic Cancer Treatment Market by Country, 2014-2025 (\$Million)
- Figure 7.52 Saudi Arabia Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.53 UAE Metastatic Cancer Treatment Market, 2014-2025 (\$million)
- Figure 7.54 South Africa Metastatic Cancer Treatment Market, 2014-2025 (\$million)

Figure 7.55 Israel Metastatic Cancer Treatment Market, 2014-2025 (\$million)

Figure 7.56 Other Metastatic Cancer Treatment Market, 2014-2025 (\$million)

Figure 8.1 Contribution of Various companies

Figure 8.2 AbbVie Inc.: Overall Product Portfolio

Figure 8.3 AbbVie Inc.: Product Portfolio for Metastatic Cancer Treatment Market

Figure 8.4 AbbVie Inc.: Overall Financials (2014-2017)

Figure 8.5 AbbVie Inc.: Revenue by Geography (2014-2017)

Figure 8.6 AbbVie Inc.: Global Presence

Figure 8.7 AbbVie Inc.: SWOT Analysis

Figure 8.8 Amgen, Inc.: Overall Product Portfolio

Figure 8.9 Amgen, Inc.: Product Portfolio for Metastatic Cancer Treatment Market

Figure 8.10 Amgen, Inc. : Overall Financials (2014-2017)

Figure 8.11 Amgen, Inc. : Revenue by Geography (2014-2017)

Figure 8.12 Amgen, Inc.: Global Presence

Figure 8.13 Amgen, Inc. : SWOT Analysis

Figure 8.14 AstraZeneca PLC: Overall Product Portfolio

Figure 8.15 AstraZeneca PLC: Product Portfolio for Metastatic Cancer Treatment Market

Figure 8.16 AstraZeneca PLC: Overall Financials (2014-2017)

Figure 8.17 AstraZeneca PLC: Revenue by Product Sales (2014-2017)

Figure 8.18 AstraZeneca PLC: Revenue by Geography (2014-2017)

Figure 8.19 AstraZeneca PLC: Global Presence

Figure 8.20 AstraZeneca PLC: SWOT Analysis

Figure 8.21 Bayer AG: Overall Product Portfolio

Figure 8.22 Bayer AG: Product Portfolio for Metastatic Cancer Treatment Market

Figure 8.23 Bayer AG: Overall Financials (2014-2017)

Figure 8.24 Bayer AG: Revenue by Geography (2014-2017)

Figure 8.25 Bayer AG: Revenue by Business Segment (2014-2015)

Figure 8.26 Bayer AG: Revenue by Buisness Segment (2016-2017)

Figure 8.27 Bayer AG: Global Presence

Figure 8.28 Bayer AG: SWOT Analysis

Figure 8.29 Boehringer Ingelheim International GmbH: Overall Product Portfolio

Figure 8.30 Boehringer Ingelheim International GmbH: Product Portfolio for Metastatic Cancer Treatment Market

Figure 8.31 Boehringer Ingelheim International GmbH: Overall Financials (2014-2017)

Figure 8.32 Boehringer Ingelheim International GmbH: Revenue by Geography (2014-2017)

Figure 8.33 Boehringer Ingelheim International GmbH: Revenue by Business Segment (2014-2015)

- Figure 8.34 Boehringer Ingelheim International GmbH: Revenue by Business Segment (2016-2017)
- Figure 8.35 Boehringer Ingelheim International GmbH: Global Presence
- Figure 8.36 Boehringer Ingelheim International GmbH: SWOT Analysis
- Figure 8.37 BRISTOL-MYERS SQUIBB COMPANY: Overall Product Portfolio
- Figure 8.38 BRISTOL-MYERS SQUIBB COMPANY: Product Portfolio for Metastatic Cancer Treatment Market
- Figure 8.39 BRISTOL-MYERS SQUIBB COMPANY: Overall Financials (2014-2017)
- Figure 8.40 BRISTOL-MYERS SQUIBB COMPANY: Revenue by Geography (2014-2017)
- Figure 8.41 BRISTOL-MYERS SQUIBB COMPANY: Global Presence
- Figure 8.42 BRISTOL-MYERS SQUIBB COMPANY: SWOT Analysis
- Figure 8.43 CELGENE CORPORATION: Overall Product Portfolio
- Figure 8.44 CELGENE CORPORATION: Product Portfolio for Metastatic Cancer Treatment Market
- Figure 8.45 CELGENE CORPORATION: Overall Financials (2014-2017)
- Figure 8.46 CELGENE CORPORATION: Revenue by Geography (2014-2017)
- Figure 8.47 CELGENE CORPORATION: Global Presence
- Figure 8.48 CELGENE CORPORATION: SWOT Analysis
- Figure 8.49 Eli-Lilly and Company: Overall Product Portfolio
- Figure 8.50 Eli-Lilly and Company: Product Portfolio for Metastatic Cancer Treatment Market
- Figure 8.51 Eli-Lilly and Company: Overall Financials (2014-2017)
- Figure 8.52 Eli-Lilly and Company: Revenue by Business segment (2014-2017)
- Figure 8.53 Eli-Lilly and Company: Revenue by Geography (2014-2017)
- Figure 8.54 Eli-Lilly and Company: Global Presence
- Figure 8.55 Eli-Lilly and Company: SWOT Analysis
- Figure 8.56 F. Hoffmann-La Roche AG: Overall Product Portfolio
- Figure 8.57 F. Hoffmann-La Roche AG: Product Portfolio for Metastatic Cancer Treatment Market
- Figure 8.58 F. Hoffmann-La Roche AG: Overall Financials (2014-2017)
- Figure 8.59 F. Hoffmann-La Roche AG: Product Sales by Region (2014-2017)
- Figure 8.60 F. Hoffmann-La Roche AG: Revenue by Division (2014-2017)
- Figure 8.61 F. Hoffmann-La Roche AG: Revenue by Pharmaceutical Sub-Segment (2014-2017)
- Figure 8.62 F. Hoffmann-La Roche AG: Global Presence
- Figure 8.63 F. Hoffmann-La Roche AG: SWOT Analysis
- Figure 8.64 JOHNSON & JOHNSON: Overall Product Portfolio
- Figure 8.65 JOHNSON & JOHNSON: Product Portfolio for Metastatic Cancer Treatment

Market

Figure 8.66 JOHNSON & JOHNSON: Overall Financials (2014-2017)

Figure 8.67 JOHNSON & JOHNSON: Revenue by Business segment (2014-2017)

Figure 8.68 JOHNSON & JOHNSON: Revenue by Geography (2014-2017)

Figure 8.69 JOHNSON & JOHNSON: Global Presence

Figure 8.70 JOHNSON & JOHNSON: SWOT Analysis

Figure 8.71 Merck & Co., Inc.: Overall Product Portfolio

Figure 8.72 Merck & Co., Inc.: Product Portfolio for Metastatic Cancer Treatment Market

Figure 8.73 Merck & Co., Inc.: Overall Financials (2014-2017)

Figure 8.74 Merck & Co., Inc.: Revenue by Business segment (2014-2017)

Figure 8.75 Merck & Co., Inc.: Revenue by Geography (2014-2017)

Figure 8.76 Merck & Co., Inc.: Global Presence

Figure 8.77 Merck & Co., Inc.: SWOT Analysis

Figure 8.78 Novartis AG: Overall Product Portfolio

Figure 8.79 Novartis AG: Product Portfolio for Metastatic Cancer Treatment Market

Figure 8.80 Novartis AG: Overall Financials (2014-2017)

Figure 8.81 Novartis AG: Revenue by Geography (2014-2017)

Figure 8.82 Novartis AG: Revenue by Business Segment (2014-2015)

Figure 8.83 Novartis AG: Revenue by Business Segment (2016-2017)

Figure 8.84 Novartis AG: Global Presence

Figure 8.85 Novartis AG: SWOT Analysis

Figure 8.86 Pfizer, Inc.: Overall Product Portfolio

Figure 8.87 Pfizer, Inc.: Product Portfolio for Metastatic Cancer Treatment Market

Figure 8.88 Pfizer, Inc.: Overall Financials (2014-2017)

Figure 8.89 Pfizer, Inc.: Revenue by Business segment (2014-2017)

Figure 8.90 Pfizer, Inc.: Revenue by Geography (2014-2017)

Figure 8.91 Pfizer, Inc.: Global Presence

Figure 8.92 Pfizer, Inc.: SWOT Analysis

Figure 8.93 SANOFI: Overall Product Portfolio

Figure 8.94 SANOFI: Product Portfolio for Metastatic Cancer Treatment Market

Figure 8.95 SANOFI: Overall Financials (2014-2017)

Figure 8.96 SANOFI: Revenue by Business Segment (2014-2015)

Figure 8.97 SANOFI: Revenue by Business Segment (2016-2017)

Figure 8.98 SANOFI: Revenue by Geography (2014-2015)

Figure 8.99 SANOFI: Revenue by Geography (2016-2017)

Figure 8.100 SANOFI: Global Presence

Figure 8.101 SANOFI: SWOT Analysis

Figure 8.102 Takeda Pharmaceutical Company Limited: Overall Product Portfolio

Figure 8.103 Takeda Pharmaceutical Company Limited: Product Portfolio for Metastatic

Cancer Treatment Market

Figure 8.104 Takeda Pharmaceutical Company Limited: Overall Financials (2014-2017)

Figure 8.105 Takeda Pharmaceutical Company Limited: Revenue by Business segment (2014-2017)

Figure 8.106 Takeda Pharmaceutical Company Limited: Revenue by Geography (2014-2017)

Figure 8.107 Takeda Pharmaceutical Company Limited: Global Presence

Figure 8.108 Takeda Pharmaceutical Company Limited: SWOT Analysis

Figure 8.109 bluebird bio, Inc.: Product Pipeline for Cancer Treatment Market

Figure 8.110 Clovis Oncology, Inc.: Product Pipeline for Cancer Treatment Market

Figure 8.111 IDERA PHARMACEUTICALS, INC.: Product Pipeline for Cancer Treatment Market

Figure 8.112 eTheRNA immunotherapies NV: Product Pipeline for Cancer Treatment Market

Figure 9.1 Global Metastatic Cancer Treatment Market Segmentation

Figure 9.2 Considered Factors for Data Prediction & Modeling

I would like to order

Product name: Global Metastatic Cancer Treatment Market – Focus on Drugs, Competitive Landscape, and Country - Analysis and Forecast (2018-2025)

Product link: <https://marketpublishers.com/r/G1AF841D9B03EN.html>

Price: US\$ 4,749.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1AF841D9B03EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

